Phase I study of docetaxel (D) in combination with epirubicin (E) as first line chemotherapy in metastatic breast cancer

被引：0
|
作者：
Borquez, D
Raab, G
Harstrick, A
Wilke, HJ
Achterrath, W
Eiermann, W
Seeber, S
机构：
[1] Rot Kreuz Hosp, Munich, Germany
[2] W German Canc Ctr, Essen, Germany
[3] Rhone Poulenc Rorer, Cologne, Germany
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
137
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [41] Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer
    M. Vassilomanolakis
    G. Koumakis
    S. Drufakou
    G. Aperis
    M. Demiri
    V. Barbounis
    J. Missitzis
    A. Efremidis
    Cancer Chemotherapy and Pharmacology, 2003, 51 : 179 - 183
  • [42] First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer
    Vassilomanolakis, M
    Koumakis, G
    Barbounis, V
    Demiri, M
    Panopoulos, C
    Chrissohoou, M
    Apostolikas, N
    Efremidis, AP
    BREAST, 2005, 14 (02): : 136 - 141
  • [43] Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer
    Vassilomanolakis, M
    Koumakis, G
    Drufakou, S
    Aperis, G
    Demiri, M
    Barbounis, V
    Missitzis, J
    Efremidis, AP
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (02) : 179 - 183
  • [44] TEXAS (Taxotere experience with anthracyclines study): an evaluation of docetaxel combined with epirubicin or doxorubicin as first line chemotherapy for metastatic breast cancer.
    Leonard, RC
    Malinovszky, KM
    Barrett-Lee, P
    Johnston, S
    Howell, A
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 272 - 272
  • [45] Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer
    Aihara, T
    Takatsuka, Y
    Itoh, K
    Sasaki, Y
    Katsumata, N
    Watanabe, T
    Noguchi, S
    Horikoshi, N
    Tabei, T
    Sonoo, H
    Hiraki, S
    Inaji, H
    ONCOLOGY, 2003, 64 (02) : 124 - 130
  • [46] Dose-finding study of high-dose epirubicin (E) and docetaxel (D) as first-line chemotherapy in advanced breast cancer (ABC)
    Pagani, O
    Sessa, C
    Vandenbulcke, T
    Martinelli, G
    Zampino, G
    Nole, F
    Zimatore, M
    Locatelli, M
    Crivellari, D
    Buonadonna, A
    Thurlimann, B
    Hess, D
    Borner, M
    Bauer, J
    Riggi, M
    Riva, A
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 1998, 9 : 16 - 16
  • [47] Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients
    Michelotti, A
    Venturini, M
    Tibaldi, C
    Bengala, C
    Gallo, L
    Carnino, F
    Del Mastro, L
    Lionetto, R
    Montanaro, E
    Rosso, R
    Conte, P
    BREAST CANCER RESEARCH AND TREATMENT, 2000, 59 (02) : 133 - 139
  • [48] Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients
    Andrea Michelotti
    Marco Venturini
    Carmelo Tibaldi
    Carmelo Bengala
    Luigi Gallo
    Flavio Carnino
    Lucia Del Mastro
    Rita Lionetto
    Elda Montanaro
    Riccardo Rosso
    Pierfranco Conte
    Breast Cancer Research and Treatment, 2000, 59 : 133 - 139
  • [49] Phase II study of the combination of docetaxel, capecitabine and carboplatinum as first line therapy in metastatic breast cancer (MBC)
    Mokaddem, Walid
    Kattan, Joseph
    Chahine, Georges
    Nasr, Fadi
    Farhat, Fadi
    Tueni, Elias
    Dagher, Joya
    Younes, Fariha
    Ghosen, Marwan
    ANNALS OF ONCOLOGY, 2004, 15 : 45 - 46
  • [50] A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer
    Cresta, S
    Grasselli, G
    Mansutti, M
    Martoni, A
    Lelli, G
    Capri, G
    Buzzi, F
    Della Cuna, GR
    Jirillo, A
    Terzoli, E
    Frevola, L
    Tarenzi, E
    Sguotti, C
    Azli, N
    Murawsky, M
    Gianni, L
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 433 - 439
12345